Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. (9th February 2019)

• Record Type: Journal Article
• Authors: Panaccione, Remo; Löfberg, Robert; Rutgeerts, Paul; Sandborn, William J; Schreiber, Stefan; Berg, Sofie; Maa, Jen-Fue; Petersson, Joel; Robinson, Anne M; Colombel, Jean-Frederic
• Is Part Of: Journal of Crohn's and colitis. Volume 13:Number 6(2019)
• Page Start: 725
• Page End: 734
• Publication Date: 2019-02-09
• Subjects: Adalimumab -- Crohn's disease -- disease duration; Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjy223
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background and Aims: Analyses of Crohn's Disease [CD] studies of anti-TNF agents, including adalimumab, have reported higher remission rates among patients with shorter disease duration. To further explore the relationship between disease duration and clinical efficacy, we analysed a larger patient cohort. Methods: Data were pooled from 10 clinical trials in patients with moderately to severely active CD who received treatment with either adalimumab or placebo. Analyses of efficacy using Crohn's Disease Activity Index [CDAI] endpoints [remission, clinical response [CR]-70, CR-100, patient-reported outcome [PRO] remission] or Harvey–Bradshaw Index [HBI] endpoints [remission/response] were conducted for induction and maintenance treatment periods. Logistic regression was used for comparisons between adalimumab and placebo treatment. Cochran–Armitage trend tests were used for comparisons between disease-duration subgroups [<1 year, ≥1–<2 years, 2–≤5 years, and >5 years]. Results: During induction, the proportion of patients achieving CDAI remission was higher in adalimumab- versus placebo-treated patients [ p <0.001] and was highest [adalimumab: 45.8%] in the <1 year subgroup compared with longer disease-duration subgroups [≥1–<2 years: 31.0%; 2–≤5 years: 23.1%; >5 years: 23.6%, Cochran–Armitage p = 0.026]. In the majority of maintenance treatment analyses, patients with <1 year disease duration had the highest efficacy responses, with statistically significant differences in remission rates across disease-duration subgroups. Conclusions: This analysis demonstrates that earlier initiation of adalimumab treatment shortly after diagnosis in patients with moderately to severely active CD leads to improved long-term clinical outcomes.